

November 2, 2007



Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th

WEST BRIDGEWATER, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that Richard T. Schumacher, PBI Founder, President, and CEO, will present a corporate overview at The Rodman & Renshaw Acumen BioFin 9th Annual Healthcare Conference in New York City on Monday, November 5, 2007 at 9:50 AM Eastern Time. The conference will be held at The New York Palace Hotel, New York City. The Company's audio portion and slides of its presentation will also be webcast live and archived for future reference at <http://www.wsw.com/webcast/rreshq12/pbio>.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements.

These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website <http://www.pressurebiosciences.com>

Investor Contacts:

Richard T. Schumacher, President & CEO

Edward H. Myles, Senior Vice President of Finance & CFO

Pressure BioSciences, Inc.

(508) 580-1818 (T)

SOURCE Pressure BioSciences, Inc.